Cargando…
Potential impact of COVID‐19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the CANNA‐TICS study
The COVID‐19 pandemic has manifold impacts on clinical trials. In response, drug regulatory agencies and public health bodies have issued guidance on how to assess potential impacts on ongoing clinical trials and stress the importance of a risk‐assessment as a pre‐requisite for modifications to the...
Autores principales: | Lasch, Florian, Guizzaro, Lorenzo, Aguirre Dávila, Lukas, Müller‐Vahl, Kirsten, Koch, Armin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014297/ https://www.ncbi.nlm.nih.gov/pubmed/33594741 http://dx.doi.org/10.1002/pst.2100 |
Ejemplares similares
-
The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders
por: Jakubovski, Ewgeni, et al.
Publicado: (2020) -
Implications for blinding in clinical trials with THC-containing cannabinoids based on the CANNA-TICS trial
por: Müller-Vahl, Kirsten R., et al.
Publicado: (2022) -
Yale Global Tic Severity Scale (YGTSS): Psychometric Quality of the Gold Standard for Tic Assessment Based on the Large-Scale EMTICS Study
por: Haas, Martina, et al.
Publicado: (2021) -
Tic disorders revisited: introduction of the term “tic spectrum disorders”
por: Müller-Vahl, Kirsten R., et al.
Publicado: (2019) -
Mind the Difference Between Primary Tics and Functional Tic‐like Behaviors
por: Müller‐Vahl, Kirsten R., et al.
Publicado: (2021)